Kornimate/medical-research-clean huggingface dataset:
management of thyroid function in hashimoto's thyroiditis during pregnancy

Conditions: Hashimoto Disease; Pregnancy Related; Thyroid Dysfunction

Summary: the management of thyroid function in pregnancy has been object of several guidelines in the last years. normal thyroid function reduces prenatal and post-natal risks and gestational complaints. trimester specific reference values of thyroid hormones and thyroid stimulating hormone (tsh) are available for selected geographic population but its are not yet are available in our country. hashimoto's thyroiditis (ht) is the most frequent autoimmune thyroid disease which can induce thyroid dysfunction, mainly sub-clinical hypothyroidism. due to the large incidence in women ht and its potential link with thyroid dysfunction this disease could be search and monitored before pregnancy. anyway a strong recommendation is to test tsh levels in all patients seeking pregnancy at risk for thyroid dysfunction for a history or current symptoms/signs of thyroid dysfunction, known positivity od thyroid autoimmunity or goiter, a history of neck radiation, age \>30 years, diabetes mellitus, previous infertility or pregnant loss, morbid obesity, living in area of moderate-severe iodine deficiency or recent administration of drugs/substance interfering with thyroid function.

the aim of the study was to retrospectively evaluate from 2011 (data of publication of the first american thyroid association (ata) guidelines for thyroid dysfunction in pregnancy) to now medical record of the a secondary level endocrine unit to verify the adherence to guidelines in the management of thyroid function in pregnant women with ht. the investigators search 1. the adherence to clinical and biochemical endocrine evaluations before conception 2. the use (correct/un-correct) of l-t4 intervention and its monitoring 3. the difference in thyroid function control between women with a fix increment of- l-t4 posology (25 mcg/week more for each 2 kg increment in body weight) after the initial l-t4 adjustment or prescription 4. the clinical and biochemical endocrine evaluation 1-2 months after delivery 5. the outcome of pregnancy 6. the e-mail up-to-date survey on current of off-springs health

Eligibility criteria:
inclusion criteria: adult ht pregnant women and adult pregnant women with nodular goiter with or whiteout previous known hypothyroidism. exclusion criteria: 1. significant pre-pregnancy comorbidity including renal failure, severe liver disease, organ transplant, cardiac failure, psychiatric conditions requiring in-patient admission, history of eating disorder. 2. unable to have e-mail address 3. unavailable written consent 4. unable understand italian language
a study investigating agent-797 in participants with relapsed/refractory solid tumors

Conditions: Tumor, Solid

Summary: this is a phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agent-797, an unmodified, allogeneic inkt cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase ii dose in solid tumors. this phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agent-797 in combination with approved immune checkpoint inhibitors (icis), including pembrolizumab and nivolumab, in participants with r/r solid tumors.


Eligibility criteria:
inclusion criteria: * histological or cytological evidence of relapsed or refractory solid tumor malignancy for which no standard therapy is available or standard therapy has failed * measurable disease per recist 1.1 as assessed by local site investigator/radiology. lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions * part 2 only, participants must have progressed per investigator assessment on pembrolizumab or nivolumab, and agree and are able to continue on the inhibitor(s) while on study * no other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the principal investigator exclusion criteria: * concurrent invasive malignancy * brain and/or leptomeningeal metastases that are untreated or require current therapy * prior radiotherapy within 2 weeks of start of study treatment

Keywords: tumor solid tumor immunotherapy inkt cells
fruquintinib combined with tas-102 in refractory metastatic colorectal cancer

Conditions: Colorectal Cancer; Metastatic Colorectal Cancer; Refractory Colorectal Carcinoma

Summary: fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mcrc), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mcrc patients. trifluridine/tipiracil (tas-102) is also a standard treatment for mcrc. this study aims to investigate the safety and effectiveness of the combined use of these two drugs in mcrc.


Eligibility criteria:
inclusion criteria: * histology-confirmed metastatic crc (mcrc) * disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab * fruquintinib administered as salvage treatment * age: 18-75 years old * informed consent exclusion criteria: * liver or kidney dysfunction, or other conditions unsuitable for chemotherapy * fruquintinib and/or tas-102 administration as second-line treatment * drug administration stopped after less than two cycles
effects of high-intensity exercise training on physical fitness, cognition, language in post-stroke aphasia

Conditions: Aphasia, Acquired; Aphasia; Aphasia, Fluent; Aphasia Non Fluent

Summary: the goal of this clinical trial is to establish the feasibility and fidelity of a high-intensity exercise program for individuals with post-stroke aphasia. the main questions it aims to answer are: * is it feasible for stroke survivors with aphasia to participate in a long in-person physical exercise program? * does participation in a physical exercise program lead to physical fitness, cognitive, language and/or psychological changes? participants can take part in two different physical exercise interventions: * low intensity intervention (control intervention); * high-intensity physical exercise intervention (target intervention).


Eligibility criteria:
inclusion criteria: * aphasia following single or multiple ischemic or hemorrhagic stroke; * at least 6 months from the last stroke; * proficient in english before the stroke; * at least 8 years of education; * between the ages of 18 and 80; * independent with ambulation without a device (single-point cane accepted); * medically stable with no contraindications to participate in regular physical exercise as determined by the patient's own primary care provider or other treating provider. exclusion criteria: * prior history of dementia, neurologic illness (other than stroke), or substance abuse; * significant visual or hearing disabilities (e.g., neglect, uncorrected visual or hearing loss) that interfere with testing; * per self-report uncontrolled cardiorespiratory and/or metabolic disorders incompatible with exercise.

Keywords: aphasia physical exercise high intensity interval training cognition physical fitness balance
the care tracker study: using patient-reported data to address racial disparity in cancer treatment

Conditions: Cancer; Breast Cancer; Colorectal Cancer

Summary: this study assesses the feasibility and acceptability of a brief electronic patient-reported outcome (epro) tool that allows patients to self-identify impending delays. the risk of treatment delays according to tumor type and race will be measured by both epro and electronic health record (ehr) tools. data from this study and the association of social determinants of health could be useful to flag patients at risk of delay and due timely intervention for modifiable treatment barriers. the prediction of the risk of treatment delay will be helpful to design another study using electronic tracking systems to prevent cancer treatment delays. the long-term goal of this research is to alert care teams when patients may be at risk of treatment days and to help patients get treatment faster. it was planned to enroll a total of 240 subjects with newly diagnosed cancer. sixty colorectal and 180 breast cancer patients will be included.


Eligibility criteria:
inclusion criteria: in order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. male and female patients of age \>18 years. 2. pathologic diagnosis of breasts or colorectal cancer within 6 weeks (42 days) prior to the enrollment date. 3. have not yet initiated cancer treatment on the date of enrollment. 4. indicate intent to receive cancer treatment at the university of north carolina. exclusion criteria: 1. patient unwilling or unable to receive electronic survey links via email or text link on a mobile device, tablet, laptop, or desktop computer. 2. patient unwilling or unable to provide verbal or signed consent to participate. 3. patient cannot read and speak english. 4. patients who do not have email access or a smartphone are able to receive short message/messaging service (sms) text messages.

Keywords: patient-reported outcome electronic health equity electronic survey treatment delay
arabin pessary in singleton pregnancy

Conditions: Previous Mid Trimester Miscarriage; Previous Preterm Birth; Previous Cervical Surgery; Short Cervix on Ultrasound

Summary: this was a retrospective study sharing the experience of women high risk for spontaneous preterm birth managed by arabin pessary.

the study recruitment was from 1st january 2013 until 31st december 2019. inclusion criteria were previous mid-trimester miscarriage and/or preterm birth, previous cervical surgery or short cervical length on routine ultrasound. the primary outcome measure was birth before 34 weeks gestation.

Eligibility criteria:
inclusion criteria: * all women high risk for spontaneous preterm birth exclusion criteria: * had arabin insertion elsewhere * delivered elsewhere * incomplete record

Keywords: arabin pessary, spontaneous preterm birth
effect of low tidal volume on blood loss during laparoscopic hepatectomy

Conditions: Blood Loss

Summary: to explore the effect of low tidal volume on blood loss and gas exchange during laparoscopic hepatectomy

background \& aims:liver cancer is an disease that threatening human health .laparoscopic hepatectomy is more and more widely used.it is very important to reduce the bleeding during laparoscopic hepatectomy.the investigators found that low tidal volume can effectively reduce intraoperative bleeding.the aim of this study was to explore the effect of low tidal volume on blood loss and gas exchange during laparoscopic hepatectomy

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 70 years old; 2. american association of anesthesiologists(asa) score i to iii; 3. ability to adhere to the study schedule; 4. ability to provide informed consent and complete all study assessments; 5. patients undergoing selective surgery of laparoscopic hepatectomy. exclusion criteria: 1. the new york heart association classification(nyha) iii to iv; 2. chronic obstructive pulmonary disease,respiratory failure, patients after thoracic surgery. 3. bmi\>32kg/m2; 4. abnormal in blood coagulation function; 5. patients with mental disease; 6. patients with neuromuscular disease; 7. concurrent enrollment in another randomized controlled trial(rct); 8. absence of written informed consent.

Keywords: laparoscopic hepatectomy low tidal volume blood loss
the use pul-042 to reduce the infection rate and progression to covid-19 in adults exposed to sars-cov-2

Conditions: COVID-19

Summary: subjects who have documented exposure to sars-cov-2 (covid-19) will receive 4 doses of pul-042 inhalation solution or 4 doses of a placebo solution by inhalation over 10 days. subjects will be followed for the incidence and severity of covid-19 over 28 days. subjects will be tested for infection with sars-cov-2 at the beginning, middle and end of the study.


Eligibility criteria:
inclusion criteria: 1. subjects must have recent exposure to sars-cov-2 (such as repeated or extensive exposure to an infected individual(s) or cohabiting with a sars-cov-2 positive individual). 2. subjects must be 50 years or older if the exposure is due to cohabitation. 3. subjects must be free of clinical signs or symptoms of a potential covid-19 diagnosis (ordinal scale of clinical improvement score of 0) with a sars-cov-2 infection symptom score (fever, cough, shortness of breath, and fatigue) of 0 in each category. 4. spirometry (forced expiratory volume in one second fev1 and forced vital capacity \[fvc\]) ≥70% of predicted value. 5. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being \< 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 6. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 7. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 8. ability to understand and give informed consent. exclusion criteria: 1. previous infection with sars-cov-2. 2. receipt of any vaccine for the prevention of covid-19 (single or multiple doses). 3. a sars-cov-2 infection symptom score greater than 0 in any of the 4 catergories (fever, cough, shortness of breath or fatigue) at the time of screening (ordinal scale for clinical improvement score of 0). 4. known history of chronic pulmonary disease (e.g., asthma \[including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection\], chronic pulmonary disease, pulmonary fibrosis, copd), pulmonary hypertension, or heart failure. 5. any condition which, in the opinion of the principal investigator, would prevent full participation
a prospective study: the value of using iflow and pbv in the endovascular treatment of infrapopliteal arterial occlusive diseases

Conditions: Arterial Occlusive Diseases

Summary: color coded blood flow and blood perfusion techniques are applied to the endovascular treatment of infrapopliteal arterial occlusion,to establish a method of quantitative evaluation of blood flow and tissue perfusion,to improve the level of calculation of condition and curative effect. so as to establish a new complete evaluation system of infrapopliteal arterial occlusive disease, to guide clinical further. at the same time establish a digital information platform for clinical, lay the foundation for the large research.


Eligibility criteria:
inclusion criteria: 1. patients are diagnosed as lower limb atherosclerosis occlusion from june 2016 to june 2018 in our centre; 2. all participating patients provided written informed consent and willing to participate; 3. aged 40 years and more; 4. the class of lower ischemia is upon 4; 5. below-the-knee arteries stenosis or occlusion is indicated by duplex or computed tomographic angiography; 6. there is no heavy stenosis in superficial femoral artery (stenosis\<30%), or short length lesion(length≤5cm, stenosis≥30%); 7. infection or ulceration don't happen in the area of surgery; 8. below the inguinal ligament arteries don't have the history of bypass or interventional surgery. exclusion criteria: 1. disagree and refuse to the free therapy; 2. lesion length of superior artery is more than 5cm; 3. history of heart dysfunction: congestive heart failure,, myocardial infarction, severe arrhythmia; 4. with severe metabolic disease, renal impairment(serum creatinine\>1.4mg/dl, glomerular filtration rate\<60) affect the excretion of contrast agents; 5. have the diseases or agents which will reduce the viable of data; 6. allergy to iodinated contrast medium.
led photobiomodulation therapy for non-specific lbp in working nurses

Conditions: Conditions for Lower Back Pain Working Nurse

Summary: background: low back pain (lbp) affects approximately 51-57% of hospital nurses and nurses' aides in europe. new high-risk groups include home- and long-term-care nurses and physiotherapists. a number of european countries are experiencing a shortage of healthcare workers. light therapy has been shown to be an effective treatment for various musculoskeletal disorders, including lateral epicondylitis, temporomandibular joint pain, carpal tunnel syndrome, and delayed-onset muscle soreness. a systematic review and meta-analysis demonstrated that low-level laser therapy is an effective method for relieving non-specific chronic low back pain (nsclbp). however, the efficacy of light-emitting diode (led) therapy for nsclbp is disputed. this study aims to evaluate the effect of led therapy on nsclbp. methods and analysis: the investigators conducted a prospective, double-blind, randomized placebo-controlled trial of 148 patients with nsclbp. the patients were randomly assigned to two groups: intervention group, where patients received led photobiomodulation therapy three times a week for 2 weeks, and the control group, where patients had sham treatment only three times a week for 2 weeks. primary outcome measures included the visual analog scale for pain, lumbar active range of motion assessments, and chair-rising times. secondary outcome measures included a multidimensional fatigue inventory, fear-avoidance beliefs questionnaire, and the oswestry disability index. the outcome measures were assessed before therapy and 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 6 months after the first interventions were completed. discussion: this study is a prospective, single-center, double-blind, randomized, controlled study. this study aims to research the efficacy of a 2-week led program for nsclbp working nurse. the results will be useful for patients, working nurses, nurses' aides, and other healthcare workers with chronic low back pain. trial registration number: this protocol was registered in clinicaltrials.gov, under the number 108-088-f.


Eligibility criteria:
inclusion criteria: * male or female registered nurses aged 18-65 years with non-specific chronic lbp, which is defined as pain or discomfort between the costal margins and inferior gluteal folds with or without referred pain to the lower limbs, and persistent lbp for at least 3 months exclusion criteria: * severe skin diseases (e.g., skin cancer, erysipelas, severe eczema, severe dermatitis, severe psoriasis, and severe hives lupus) * lbp associated with nerve root compromise (measured by clinical examination of dermatomes, myotomes, and reflexes) * serious spinal pathologies, such as fractures, tumors, and inflammatory and infectious diseases * decompensated heart disease or metabolic disorders * previous spinal surgery * pregnancy.

Keywords: led lbp photobiomodulation nurse
bondir study: a study of intravenous bonviva (ibandronate) after recent vertebral osteoporotic fracture in patients with osteoporosis.

Conditions: Osteoporosis

Summary: this 2 arm study will assess the efficacy and safety of intravenous bonviva in patients with osteoporosis experiencing pain after recent vertebral osteoporotic fracture. patients will be randomized to receive either bonviva (3mg i.v. bolus injection) or placebo. the anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * postmenopausal women or men \>30 years of age; * osteoporosis; * vertebral osteoporotic fracture in past 4 weeks; * fracture-related pain requiring analgesic treatment. exclusion criteria: * non-menopausal women; * current treatment with another bisphosphonate; * current treatment with class iii analgesics.
pivotal response treatment for individuals with intellectual disabilities

Conditions: Intellectual Disabilities; Speech Delay; Language Disorder

Summary: the investigators will assess the efficacy of pivotal response treatment (prt) in the treatment of communication deficits in children with intellectual disabilities. by collecting information about parent and child functioning before and after prt, the investigators will be able to determine whether the intervention is effective in improving child communication and reducing parent stress.


Eligibility criteria:
inclusion criteria for individuals with intellectual disabilities: * participants will have an age range between 2 and 17.11 years of age inclusive * male or female * diagnosis of an intellectual disability based on the fourth edition of the diagnostic and statistical manual of mental disorders (dsm-iv-tr), the 10th revision of the international statistical classification of diseases and related health problems (icd-10), and an expert clinical evaluation * have historical evidence of significant abnormal developmental milestones as determined by neurological history * care provider that will reliably bring subject to study visits, and is trustworthy to provide accurate accounts of services provided to the subject inclusion criteria for individuals with speech delay/language disorder: * participants will have an age range between 2 and 17.11 years of age inclusive * male or female * diagnosis of a speech delay based on the fourth edition of the diagnostic and statistical manual of mental disorders (dsm-iv-tr), the 10th revision of the international statistical classification of diseases and related health problems (icd-10), and an expert clinical evaluation * preschool language scale (pls) score of at least 1 standard deviations below age level (for children in the age range of 2-6.11) * care provider that will reliably bring subject to study visits, and is trustworthy to provide accurate accounts of services provided to the subject exclusion criteria: * medically unstable (such as having unstable seizures) * primary diagnosis of autism spectrum disorder (asd) is exclusionary as determined by the investigators

Keywords: intellectual disabilities speech delay language disorder